AUTHOR OF THIS BLOG

DR ANTHONY MELVIN CRASTO, WORLDDRUGTRACKER

Experimental Drug Shows Benefits Against Melanoma in Early Study, Lambrolizumab activates body’s immune system to kill cancerous cells, researchers say

 Uncategorized  Comments Off on Experimental Drug Shows Benefits Against Melanoma in Early Study, Lambrolizumab activates body’s immune system to kill cancerous cells, researchers say
Jun 032013
 

Experimental Drug Shows Benefits Against Melanoma in Early Study
U.S. News & World Report
SUNDAY, June 2 (HealthDay News) — A new drug called lambrolizumab appears to improve outcomes in patients with advanced melanoma, according to the results of a phase 1 trial. Lambrolizumab is an antibody that works by revealing the cancer to the immune system so it can mount a response and kill the cancer cells with few serious side effects, the researchers said.

read all at

http://health.usnews.com/health-news/news/articles/2013/06/02/experimental-drug-shows-benefits-against-melanoma-in-early-study

volleyball

by WORLD DRUG TRACKER

DR ANTHONY CRASTO

Share

Chinese researchers have developed the world’s first ever vaccine against a strain of enterovirus that can cause hand, foot and mouth disease,

 drugs  Comments Off on Chinese researchers have developed the world’s first ever vaccine against a strain of enterovirus that can cause hand, foot and mouth disease,
Jun 032013
 

World First Hand' Foot And Mouth Vaccine Developed

AsianScientist (Jun. 3, 2013) – By Sunanda Creagh – Chinese researchers have developed the world’s first ever vaccine against a strain of enterovirus that can cause hand, foot and mouth disease, a condition commonly affecting small children that can lead to deadly infection of the brain and spinal cord membranes.

read all at

http://www.asianscientist.com/health-medicine/world-hand-foot-mouth-vaccine-developed-2013/

Share

GSK, Genmab announce positive results from Phase III study of Arzerra (ofatumumab)

 drugs  Comments Off on GSK, Genmab announce positive results from Phase III study of Arzerra (ofatumumab)
Jun 012013
 

may30,2013–GlaxoSmithKline (GSK) and Genmab (GEN) have announced positive results from Phase III study of Arzerra (ofatumumab) in combination with chlorambucil for the treatment of chronic lymphocytic leukaemia (CLL) patients.

Share

Discovery of Unexpectedly Active Group-Introduction of a sulfoximine group into anticancer candidates shows that sometimes sticking to the unconventional pays off

 Uncategorized  Comments Off on Discovery of Unexpectedly Active Group-Introduction of a sulfoximine group into anticancer candidates shows that sometimes sticking to the unconventional pays off
May 312013
 

thumbnail image: Discovery of Unexpectedly Active Group

Introduction of a sulfoximine group into anticancer candidates shows that sometimes sticking to the unconventional pays off

Read more

Share

A Drug Discovery Detective Story-Biological activity of small-molecule RNA polymerase (RNAP) inhibitors revealed to come from polymeric impurity

 Uncategorized  Comments Off on A Drug Discovery Detective Story-Biological activity of small-molecule RNA polymerase (RNAP) inhibitors revealed to come from polymeric impurity
May 312013
 

thumbnail image: A Drug Discovery Detective Story

Biological activity of small-molecule RNA polymerase (RNAP) inhibitors revealed to come from polymeric impurity

Read more

Share

Study: Lilly’s Forteo Increases Bone Mineral Density in Men

 drugs  Comments Off on Study: Lilly’s Forteo Increases Bone Mineral Density in Men
May 312013
 

FORTEO (teriparatide [rDNA origin]) Structural Formula Illustration

New Data on FORTEO® (teriparatide [rDNA origin] injection) Show Increased Bone Mineral Density in Men with Glucocorticoid-Induced Osteoporosis

http://www.pharmalive.com/study-lillys-forteo-increases-bone-mineral-density-in-men

Share
 Older Entries  Newer Entries
Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: